Clinical trials: Cancer Disease Progression
HCC - Hepatocellular Carcinoma
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
The goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization/ hepatic arterial infusion chemotherapy (TACE/HAIC) plus second-line…
- Trial name
- NCT07187284
- Testing
- EDN combined with TACE/HAIC and Immuno-Targeted Therapy, TACE/HAIC plus Immuno-Targeted Therapy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhongda Hospital
Prostate Cancer
A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer
A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer,Assigned to Active Surveillance who…
- Trial name
- NCT03348527
- Testing
- 2-Hydroxyflutamide Depot
- Where
- 10 sites in Canada, Finland and 1 more
- Volunteers
- 61 people
- Sponsor
- Lidds AB
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Phase II Study of Everolimus Beyond Progression
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT02269670
- Testing
- everolimus, anastrozole, letrozole
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come back.
- Conditions
- KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02642042
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Trametinib
- Where
- 596 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Prostatic Neoplasms
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy
Background: Pox viral vectors can induce a PSA-specific T-cell responses and clinical responses in patients with advanced prostate cancer.
- Trial name
- NCT00096551
- Testing
- Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma, Sarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon…
- Trial name
- NCT05135975
- Testing
- Cabozantinib
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Nationwide Children's Hospital
Melanoma
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior…
- Trial name
- NCT04068181
- Testing
- Talimogene laherparepvec, Pembrolizumab
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Astrocytoma, Glioblastoma
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for…
- Conditions
- Astrocytoma, Glioblastoma, Progressive Disease
- Trial name
- NCT07560865
- Testing
- FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
HER2-mutant Non-Small Cell Lung Cancer
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
- Trial name
- DL-05 (NCT05246514)
- Testing
- Trastuzumab deruxtecan
- Where
- 28 sites in China
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Prostate Cancer
Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer
RATIONALE: Dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery. PURPOSE: This randomized phase II trial is studying a soy supplement to see how well it works compared to…
- Trial name
- NCT00345813
- Testing
- soy isoflavones, soy protein isolate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer.
- Trial name
- NCT01399190
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
- Trial name
- NCT00290810
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02503722
- Testing
- Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study
- Where
- 5 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Kidney Cancer
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.
- Trial name
- NCT01392183
- Testing
- Pazopanib, Temsirolimus, Quality of Life Assessment
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate the progression-free survival during maintenance therapy. Eligible patients will be treated within a 12-week induction therapy.
- Trial name
- PanaMa (NCT01991873)
- Testing
- Maintenance Chemotherapy, Panitumumab (Within maintenance phase), mFOLFOX6 (Within re-induction phase)
- Where
- 2 sites in Germany
- Volunteers
- 387 people
- Sponsor
- AIO-Studien-gGmbH
EGFR Positive Non-small Cell Lung Cancer
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC
Tyrosine kinase inhibitors (TKI) have greatly improved prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), with tumor responses in the majority of cases and a median overall survival…
- Trial name
- NCT04105153
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Thoraxklinik-Heidelberg gGmbH
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition…
- Trial name
- NCT00444587
- Testing
- Second line chemotherapy, trastuzumab [Herceptin]
- Where
- 30 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
The purpose of this study is to investigate the safety and efficacy of giving atezolizumab combined with bevacizumab in patients with stage 4 epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) whose…
- Trial name
- NCT04099836
- Testing
- Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.